SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate sodium/glucose channels in the intestinal mucosa. The foremost metabolic effect appears to show that this pharmaceutical class inhibits reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (T2DM). Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in T2DM patients. Several medications of this class have been approved or are currently under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure. Currently there are three SGLT2 selective inhibitors approved by the Food and Drug Administration (FDA) for mono, dual, and triple therapy: canagliflozin (Invokana®), dapagliflozin (Farxiga®) and empagliflozin (Jardiance®) Satyendra Dhar MD, @DharSaty #SGLT2inhibitors, #type2diabetes, #canagliflozin, #dapagliflozin, #empagliflozin
